Announcements Trials
Browse Landscape

Phase

Phase 2 19Phase 1 7Phase 3 3Phase 1/2 3Phase NA 2

Status

Completed 124Recruiting 26Unknown 23Active not recruiting 23Terminated 21Withdrawn 3Suspended 1Enrolling by invitation 1

Sponsor Class

OTHER 1NIH 1INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2

Conditions

Leukemia 2Recurrence 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma, Follicular 1

Interventions

Cisplatin 22Carboplatin 15Radiotherapy 13Paclitaxel 11Gemcitabine 10Rituximab 9Fluorouracil 9Drug Therapy 6Dexamethasone 5Cyclophosphamide 5Capecitabine 5Bevacizumab 5Vinorelbine 4Pemetrexed 4Nivolumab 4Methotrexate 4Etoposide 4Docetaxel 4Bendamustine Hydrochloride 4spartalizumab 3pertuzumab 3pembrolizumab 3fludarabine 3Vincristine 3Trastuzumab 3Surgical Procedures, Operative 3Standard of Care 3Prednisone 3Oxaliplatin 3Lenalidomide 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 3 × Withdrawn × Prednisone × Clear all
NCT06313996 2026-03-18

A Study to Evaluate the Efficacy and Safety of Liso-cel Compared to Standard of Care in Adults With Relapsed or Refractory Follicular Lymphoma

Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

Phase 3 Withdrawn
Lymphoid

Lymphoma, Follicular, Recurrence

NCT00488605 2023-08-03

H-9926-LCH III: Treatment Protocol of the Third International Study for Langerhans Cell Histiocytosis

University of New Mexico

Phase 3 Withdrawn
Other hematologic neoplasm

Leukemia

NCT00019409 2012-03-23

Radiation Therapy to the Head or Intrathecal Chemotherapy Plus High Dose Cytarabine in Preventing CNS Disease in Children With Acute Lymphoblastic Leukemia

National Institutes of Health Clinical Center (CC)

Phase 3 Withdrawn
LymphoidOther hematologic neoplasm

Leukemia, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡